{"id":2853,"date":"2018-08-07T17:48:50","date_gmt":"2018-08-07T12:18:50","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2853"},"modified":"2021-07-24T12:57:01","modified_gmt":"2021-07-24T07:27:01","slug":"notizia-68","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-68","title":{"rendered":"Progenics got FDA Approval; Curcumin to cancer cells"},"content":{"rendered":"<h3 style=\"background: white;\"><b><span style=\"font-family: 'Helvetica','sans-serif'; color: #333333;\">Progenics got FDA Approval on Iobenguane I 131 for Rare Adrenal Gland Tumors<\/span><\/b><\/h3>\n<article id=\"node-472973\" class=\"node node-article node-promoted view-mode-full\"><span style=\"box-sizing: border-box;\">\u00a0A good news for unresectable rare adrenal tumor\u00a0 patients as oncologists now have a new treatment to offer .<\/span><span style=\"font-size: 10.5pt; font-family: 'Helvetica','sans-serif'; color: #333333; background: white;\"> On July 30, 2018, the Food and Drug Administration approved Progenics Pharmaceuticals iobenguane I for adult and pediatric patients with iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma (PPGL) who require systemic anticancer therapy.<\/span> <span style=\"font-family: 'inherit','serif';\">Pheochromocytomas are rare tumors of the adrenal glands. The FDA approval of iobenguane I 131 was based on data from a pivotal phase II, open-label, multicenter trial that was conducted under a SPA with the FDA.\u00a0 Iobenguane I 131, is a radiolabeled molecule similar to noradrenaline. Iobenguane I 131 comes with a warning about radiation exposure to patients and family members. The risk of radiation exposure is greater in pediatric patients, according to the FDA.<\/span><\/article>\n<article><\/article>\n<article>\n<h3><strong>A new method to deliver herbal supplement curcumin to cancer cells by solving its insolubility has been discoved by the researchers<\/strong><\/h3>\n<p>Curcumin known for its therapeutic effect and as a way to kill germs present in raw meat. It is \u00a0an effective agent for killing cancer cells.Recently, however, Pan&#8217;s laboratory collaborated with Peter Stang on ways to be able to render curcumin soluble, deliver it to infected tumors, and kill\u00a0cancer\u00a0cells. The team has created a sophisticated metallocyclic complex using platinum that has not only enabled curcumin&#8217;s solubility, but whose synergy has proven 100 times more effective in treating various cancer types such as melanoma and\u00a0breast cancer cells\u00a0.They have developed a complex &amp; has a very unique ability to take on different forms of material\u2014from a spherical nanoparticle to longer elongated threads of nanometer size.This drug can be given both orally and intravenously.Even if you are killing all the cells in the tumor, there would be a tiny population of cells with &#8216;stemness&#8217; properties that could enable\u00a0cancer cells\u00a0to grow back and spread to other parts of the body. However, if we can deliver therapy to cancer stem\u00a0cells, we can prevent that from happening.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Progenics got FDA Approval on Iobenguane I 131 for Rare Adrenal Gland Tumors \u00a0A good news for unresectable rare adrenal tumor\u00a0 patients as oncologists now have a new treatment to offer . On July 30, 2018, the Food and Drug Administration approved Progenics Pharmaceuticals iobenguane I for adult and pediatric patients with iobenguane scan-positive, unresectable, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2290,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17643,137,17642],"industry":[17225],"therapeutic_areas":[17228,17234],"class_list":["post-2853","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-adrenal-gland-tumors","tag-cancer","tag-curcumin","industry-pharmaceutical","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FDA Nod to Progenics; Research suggests Curcumin to cure cancer cells<\/title>\n<meta name=\"description\" content=\"Good news for unresectable rare adrenal tumour patients as oncologists now have a new treatment to offer. On July 30, 2018...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-68\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Nod to Progenics; Research suggests Curcumin to cure cancer cells\" \/>\n<meta property=\"og:description\" content=\"Good news for unresectable rare adrenal tumour patients as oncologists now have a new treatment to offer. On July 30, 2018...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-68\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-08-07T12:18:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"620\" \/>\n\t<meta property=\"og:image:height\" content=\"414\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Nod to Progenics; Research suggests Curcumin to cure cancer cells","description":"Good news for unresectable rare adrenal tumour patients as oncologists now have a new treatment to offer. On July 30, 2018...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-68","og_locale":"en_US","og_type":"article","og_title":"FDA Nod to Progenics; Research suggests Curcumin to cure cancer cells","og_description":"Good news for unresectable rare adrenal tumour patients as oncologists now have a new treatment to offer. On July 30, 2018...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-68","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-08-07T12:18:50+00:00","article_modified_time":"2021-07-24T07:27:01+00:00","og_image":[{"width":620,"height":414,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-68","url":"https:\/\/www.delveinsight.com\/blog\/notizia-68","name":"FDA Nod to Progenics; Research suggests Curcumin to cure cancer cells","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-68#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-68#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","datePublished":"2018-08-07T12:18:50+00:00","dateModified":"2021-07-24T07:27:01+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Good news for unresectable rare adrenal tumour patients as oncologists now have a new treatment to offer. On July 30, 2018...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-68"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-68#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","width":620,"height":414,"caption":"Entasis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing-300x200.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Adrenal Gland Tumors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Curcumin<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Adrenal Gland Tumors<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Curcumin<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 7, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 7, 2018 5:48 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2853"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2853\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2290"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2853"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2853"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2853"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2853"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}